The Dx-AF study: a prospective, multicenter, randomized controlled trial comparing VDD-ICD to VVI-ICD in detecting sub-clinical atrial fibrillation in defibrillator patients.

PubWeight™: 0.75‹?›

🔗 View Article (PMID 28752228)

Published in J Interv Card Electrophysiol on July 27, 2017

Authors

Mohammed Shurrab1,2,3, Amir Janmohamed4, Jean-François Sarrazin5, Felix Ayala-Paredes6, Marcio Sturmer7, Randall Williams8, Satish Toal9, Chris Lane10, Kevin E Thorpe11,12, Jeff S Healey13, Eugene Crystal14,15

Author Affiliations

1: Arrhythmia Services, Schulich Heart Centre, Sunnybrook Health Sciences Centre, University of Toronto, 2075 Bayview Avenue, Suite D-377, Toronto, Ontario, M4N 3M5, Canada.
2: Division of Cardiology, Women's College Hospital, University of Toronto, Toronto, Ontario, Canada.
3: Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada.
4: Rouge Valley Health System, Scarborough, Ontario, Canada.
5: Department of Cardiology, Institut Universitaire de Cardiologie et Pneumologie de Québec, Laval University, Québec, Canada.
6: Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, Quebec, Canada.
7: Sacre-Coeur Hospital, Université de Montréal, Montréal, Québec, Canada.
8: CK Hui Heart Centre, Royal Alexandra Hospital, University of Alberta, Edmonton, Alberta, Canada.
9: Saint John Regional Hospital, Saint John, New Brunswick, Canada.
10: Royal Jubilee Hospital, Victoria, British Columbia, Canada.
11: Dalla Lana School of Public Health, University of Toronto, Toronto, Canada.
12: Applied Health Research Centre, Li Ka Shing Knowledge Institute of St. Michael's Hospital, Toronto, Canada.
13: Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada.
14: Arrhythmia Services, Schulich Heart Centre, Sunnybrook Health Sciences Centre, University of Toronto, 2075 Bayview Avenue, Suite D-377, Toronto, Ontario, M4N 3M5, Canada. Eugene.Crystal@sunnybrook.ca.
15: Division of Cardiology, Women's College Hospital, University of Toronto, Toronto, Ontario, Canada. Eugene.Crystal@sunnybrook.ca.

Articles cited by this

Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med (2009) 12.44

Subclinical atrial fibrillation and the risk of stroke. N Engl J Med (2012) 11.11

Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation (2004) 8.80

Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC Study: a randomized trial. JAMA (2006) 3.84

Atrial high rate episodes detected by pacemaker diagnostics predict death and stroke: report of the Atrial Diagnostics Ancillary Study of the MOde Selection Trial (MOST). Circulation (2003) 3.57

2012 ACCF/AHA/HRS focused update incorporated into the ACCF/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol (2012) 3.25

2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J (2016) 2.70

Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a retrospective analysis of the SOLVD trials. Studies of Left Ventricular Dysfunction. J Am Coll Cardiol (1998) 2.21

Projections on the number of individuals with atrial fibrillation in the European Union, from 2000 to 2060. Eur Heart J (2013) 2.17

Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: insight from the Studies Of Left Ventricular Dysfunction (SOLVD) trials. Circulation (2003) 2.16

Clinical efficacy and safety of an implantable cardioverter-defibrillator lead with a floating atrial sensing dipole. Pacing Clin Electrophysiol (2013) 2.02

Dual-chamber implantable cardioverter-defibrillator selection is associated with increased complication rates and mortality among patients enrolled in the NCDR implantable cardioverter-defibrillator registry. J Am Coll Cardiol (2011) 1.85

Reduced risk for inappropriate implantable cardioverter-defibrillator shocks with dual-chamber therapy compared with single-chamber therapy: results of the randomized OPTION study. JACC Heart Fail (2014) 1.74

Comparison of a novel, single-lead atrial sensing system with a dual-chamber implantable cardioverter-defibrillator system in patients without antibradycardia pacing indications: results of a randomized study. Circ Arrhythm Electrophysiol (2010) 1.72

Cardiovascular outcomes with atrial-based pacing compared with ventricular pacing: meta-analysis of randomized trials, using individual patient data. Circulation (2006) 1.67

Clinical relevance of silent atrial fibrillation: prevalence, prognosis, quality of life, and management. J Interv Card Electrophysiol (2000) 1.65

Association of single- vs dual-chamber ICDs with mortality, readmissions, and complications among patients receiving an ICD for primary prevention. JAMA (2013) 1.51

EuroEco (European Health Economic Trial on Home Monitoring in ICD Patients): a provider perspective in five European countries on costs and net financial impact of follow-up with or without remote monitoring. Eur Heart J (2014) 1.51

Evaluation of early complications related to De Novo cardioverter defibrillator implantation insights from the Ontario ICD database. J Am Coll Cardiol (2010) 1.41

Variation in use of dual-chamber implantable cardioverter-defibrillators: results from the national cardiovascular data registry. Arch Intern Med (2012) 1.24

Implantable cardioverter defibrillator system with floating atrial sensing dipole: a single-center experience. Pacing Clin Electrophysiol (2014) 1.14

VDD vs DDD pacemakers: a meta-analysis. Can J Cardiol (2014) 0.89

Current practice for diagnosis and management of silent atrial fibrillation: results of the European Heart Rhythm Association survey. Europace (2013) 0.89

Implantation of a dual chamber pacing and sensing single pass defibrillation lead. Pacing Clin Electrophysiol (2001) 0.87

Clinical significance of atrial fibrillation detected by cardiac implantable electronic devices. Heart Rhythm (2014) 0.82

VDD pacing: under evaluated, undervalued, and underused. Pacing Clin Electrophysiol (2004) 0.81

Performance of a new atrial fibrillation detection algorithm in a miniaturized insertable cardiac monitor: Results from the Reveal LINQ Usability Study. Heart Rhythm (2016) 0.81

Atrial electrograms improve the accuracy of tachycardia interpretation from ICD and pacemaker recordings: The RATE Registry. Heart Rhythm (2016) 0.78

Performance of Atrial Fibrillation Detection in a New Single-Chamber ICD. Pacing Clin Electrophysiol (2016) 0.77

Sextapolar catheter electrode for temporary sequential atrioventricular pacing. Cardiovasc Res (1974) 0.77

European clinical experience with a dual chamber single pass sensing and pacing defibrillation lead. Pacing Clin Electrophysiol (2002) 0.77

Chronic experiences with a single lead dual chamber implantable cardioverter defibrillator system. Pacing Clin Electrophysiol (2003) 0.77

Probing oral anticoagulation in patients with atrial high rate episodes: Rationale and design of the Non-vitamin K antagonist Oral anticoagulants in patients with Atrial High rate episodes (NOAH-AFNET 6) trial. Am Heart J (2017) 0.77

Single lead for permanent physiological cardiac pacing. Lancet (1978) 0.77

Rationale and design of the Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation (ARTESiA) trial. Am Heart J (2017) 0.76

Real-world performance of an enhanced atrial fibrillation detection algorithm in an insertable cardiac monitor. Heart Rhythm (2016) 0.76

Silent ischaemic brain lesions related to atrial high rate episodes in patients with cardiac implantable electronic devices. Europace (2014) 0.76

Articles by these authors

Perioperative atrial fibrillation and the long-term risk of ischemic stroke. JAMA (2014) 3.59

Reduced risk for inappropriate implantable cardioverter-defibrillator shocks with dual-chamber therapy compared with single-chamber therapy: results of the randomized OPTION study. JACC Heart Fail (2014) 1.74

Canadian Heart Rhythm Society and Canadian Association of Radiologists consensus statement on magnetic resonance imaging with cardiac implantable electronic devices. Can J Cardiol (2014) 0.83

Management of patients with implantable cardioverter-defibrillators and pacemakers who require radiation therapy. Heart Rhythm (2015) 0.82

Canadian Heart Rhythm Society and Canadian Association of Radiologists consensus statement on magnetic resonance imaging with cardiac implantable electronic devices. Can Assoc Radiol J (2014) 0.82

Insight into the mechanism of failure of the Riata lead under advisory. Heart Rhythm (2014) 0.80

Canadian Cardiovascular Society/Canadian Association of Interventional Cardiology/Canadian Society of Cardiac Surgery position statement on revascularization--multivessel coronary artery disease. Can J Cardiol (2014) 0.78

Comparison of dabigatran versus warfarin in diabetic patients with atrial fibrillation: Results from the RE-LY trial. Int J Cardiol (2015) 0.77

Relation between detection rate and inappropriate shocks in single versus dual chamber cardioverter-defibrillator - an analysis from the OPTION trial. Sci Rep (2016) 0.75

What Do Implanted Cardiac Monitors Reveal About Atrial Fibrillation? JAMA Cardiol (2017) 0.75

Early Life Risk Factors for Incident Atrial Fibrillation in the Helsinki Birth Cohort Study. J Am Heart Assoc (2017) 0.75

North American Thrombosis Forum, AF Action Initiative Consensus Document. Am J Med (2016) 0.75

Device-detected subclinical atrial tachyarrhythmias: definition, implications and management-an European Heart Rhythm Association (EHRA) consensus document, endorsed by Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS) and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLEACE). Europace (2017) 0.75